Effect of growth hormone replacement therapy on cognition after traumatic brain injury.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Post-traumatic hypopituitarism, and specifically growth hormone deficiency (GHD), has been found in a large percentage of individuals with chronic moderate to severe TBI.

Presently, there are no published treatment studies of hormone replacement in this population.

Who Took Part

According to the abstract, 83 subjects were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults.

How the Study Was Run

The researchers set it up as a randomized, placebo-controlled and pilot study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

What Was Measured

PubMed files the paper under topics including Brain Injuries, Cognition, Hormone Replacement Therapy, Human Growth Hormone and Neuropsychological Tests.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 83 subjects.

The publication is from 2010 (Journal of neurotrauma), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.